ArticleFrontiers in medicine2025
Different low activated clotting time target anticoagulation protocols for patients during extracorporeal membrane oxygenation management: a retrospective cohort study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anticoagulation management is crucial for patients to prevent serious complications during extracorporeal membrane oxygenation (ECMO). However, the optimal target for low activated clotting time (ACT) anticoagulation during ECMO remains unclear. Methods: A retrospective cohort study was conducted, including patients who received ECMO support in the Second Affiliated Hospital of Harbin Medical University in China from April 2017 to May 2024. Eligible patients were categorized into low (<160 s), medium (160-180 s), and high (>180 s) ACT groups. Major outcomes included ECMO oxygenator change, bleeding and thromboembolic events. Results: A total of 148 patients were included after applying the exclusion criteria and divided into the low ACT group ( Conclusion: Different low ACT target anticoagulation protocols for patients during ECMO do not increase the risk of oxygenator change, bleeding and thromboembolism during ECMO management. These results can help clinicians choose appropriate ACT target anticoagulation for patients. Further prospective trials are needed to verify the low ACT target anticoagulation protocols. Clinical trial registration: Chinese Clinical Trial Registry, ChiCTR2500100151, Registered 3 April, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.